Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS626 versus Remicade in moderate to severe chronic plaque psoriasis
ChiCTR2000034243Phase 3Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of infliximab in plaque psoriasis (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of patients achieving PASI 75 at week 10. Started Jun 2020; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2000034243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034243.